Key Takeaways

• Only three of the seven platforms here use the word agent about themselves, so the category label sorts vendors far less reliably than two concrete questions do.
• Converge Bio ranks first for a team that intends to maintain its own pipeline, closing the loop on managed wet-lab validation while holding no drug assets.
• The hardest physical loops in this market belong to vendors advancing their own molecules, which makes autonomy and independence difficult to buy together.
• Every performance figure in this category is vendor-reported, so method disclosure matters more than headline multiples when comparing claims.

The word agentic arrived in drug discovery faster than any shared definition of it. A system that reads ten thousand papers and proposes a target is called an agent. So is a model that generates a sequence in one pass, and so is a robot arm running a protocol somebody else wrote. FutureHouse, the nonprofit research lab behind several of the field’s best-known agents, draws the line usefully: an AI scientist “actually runs a loop: it builds a model of the world, generates hypotheses from that model, tests them, and updates the model based on new data.” The same page adds the sentence most vendors leave out: no system has fully cleared that bar yet, including theirs.

At a Glance

1. Converge Bio: antibody design whose loop closes on managed wet-lab validation for the customer’s own pipeline
2. Edison Scientific: the most literal agent here, steering and branching investigations mid-run
3. CytoReason: the only named, dated agent product in the category, built on computational disease models
4. Deep Origin: agent-branded tools plus software a customer’s own team runs
5. Terray Therapeutics: an industrial measurement engine feeding a fully closed chemistry loop
6. Chemify: robotic synthesis driven by a chemical programming language
7. Turbine: simulation at scale deciding which few experiments reach a bench

What Separates a Real Loop From a Good Prediction

Before comparing features, settle what the system is allowed to do and what it does with the answer:

• Planning versus one-shot output. An agent chooses its next action. A generative model returns candidates and stops. Both are useful, and only one of them changes course when a result disappoints.
• The physical gap. Most systems marketed as agents cannot touch an experiment. Hypotheses, analysis and even figures can be machine-generated while human hands do everything at the bench.
• Who holds the output. A vendor running its own discovery programs  is a competitor for the same molecules, however good the tooling it sells alongside.

Answer those three, and the roster below sorts itself without reference to the word “agentic” at all.

7 Top Agentic AI Drug Discovery Solutions

1. Converge Bio

Converge Bio is the best agentic AI drug discovery solution for a team that intends to keep its own pipeline, because its loop closes on wet-lab evidence and it builds no drugs of its own. ConvergeAB takes a sequence for optimization, a target product profile and an antigen sequence and structure, then optimizes affinity, stability, solubility, immunogenicity and expression in a single design pass across IgG, scFv, VHH and bispecific formats.

Eight capabilities are named, including affinity maturation, developability and expression optimization, humanization, cross-reactivity tuning, pH-dependent binding, and both IP generation and IP fortification. The model is trained on a trillion natural protein tokens, seven million antibody sequences, three million antibody-antigen pairs and a hundred thousand fully characterized antibodies.

What places it first is the shape of the engagement, not the model. Tens to hundreds of thousands of in silico candidates are narrowed to roughly forty-eight for screening per round, on a six-week iterate-and-refine cycle, and Converge manages the wet-lab validation through partner CROs rather than handing over a file. Its own description is working as an AI-Lab partner in a closed loop until the customer’s team has validated, development-ready solutions.  

Key features:

• Multi-property optimization that raises, lowers or holds each property as a programme requires
• Wet-lab validation managed through partner CROs on a roughly six week design cycle
• Private customer instance, with customer data excluded from base-model training
• No internal drug pipeline, so the platform competes for no molecules of its own
• Antibody formats spanning IgG, scFv, VHH and bispecifics

2. Edison Scientific

Edison Scientific publishes the most literal agentic description in this market. Its Kosmos system reads literature, analyses data, generates hypotheses, steers investigations mid-run, branches hypotheses and executes workflows autonomously, built on what the company calls structured world models. A single run is described as reading 1,500 papers and running 42,000 lines of analysis code, with the agent provisioning its own compute for docking.

Key features:

• Mid-run steering and hypothesis branching rather than one-shot generation
• On-premise deployment with SOC 2 Type II and integration into existing lab data systems
• Published accuracy rate and documented failure modes
• Named pharmaceutical partnership with Incyte, with no financial terms disclosed

3. CytoReason

CytoReason offers the only named and dated agent product in this comparison. LINA, announced in January 2026, is described as an AI agent for pharmaceutical research and development, accelerated by NVIDIA and built on the company’s computational disease models. It is trained on hundreds of drug-development questions used across the industry, produces grounded analysis plans with reproducible code, and the company references scalable multi-agent scientific workflows.

Key features:

• A named, dated agent product built on validated computational disease models
• Reproducible analysis code and grounded analysis plans as outputs
• Deep named pharmaceutical evidence including Pfizer, Sanofi and Takeda
• Delivered through collaboration and licensing rather than self-serve access

4. Deep Origin

Deep Origin is the entry that most resembles software a customer actually operates. Its platform spans docking, free energy perturbation and ADMET prediction, reached three ways: a subscription starting at thirty-two dollars a month, a code-first API, and research partnerships with milestones and optional IP co-ownership. DO Patent is described outright as an AI agent that extracts full molecular structures from patents and scientific PDFs.

Key features:

• Self-serve subscription and a code-first API, unusual in this category
• Agent-branded patent extraction and a conversational discovery assistant
• Physical loop pursued through a named ARIA programme with a robotics partner
• Academic users named in page text, with pharmaceutical logos reflecting team history

5. Terray Therapeutics

Terray has the most convincing physical loop here and the hardest numbers behind it, which is why it belongs in the list despite claiming nothing agentic at all. Its EMMI platform combines ultra-miniaturized molecule testing hardware with a highly automated laboratory and a full-stack AI layer, grounded in a dataset the company puts at fourteen billion unique target-molecule measurements, growing by roughly a billion per quarter. Its COATI3 foundation model is trained on over a billion diverse molecules.

Key features:

• Fourteen billion target-molecule measurements generated in its own automated lab
• COATI3 foundation model trained on over a billion molecules
• Named partnered programs  with Bristol Myers Squibb, Gilead and Odyssey Therapeutics
• Internal pipeline advancing alongside partner work

6. Chemify

Chemify closes a physical loop in its own facility, and does it in chemistry rather than biology. Its chemputation approach translates target molecules into chemical code that runs directly on robotic systems, enabling what the company describes as fully automated design-make-test-analyse cycles that remove the synthesis bottleneck. The stack includes an ASSEMBLER layer for route optimization, a chemputability score for whether a molecule can actually be made, and a universal chemical programming language.

Key features:

• Robotic synthesis at gram scale in its own Glasgow facility
• A chemical programming language encoding reproducible synthesis plans
• Makeability scoring before synthesis is attempted
• Three peer-reviewed validation papers published in April 2026

7. Turbine

Turbine is the clearest counter-example in this list, and that is precisely its value. Its vLab platform runs what the company puts at more than fifty million virtual experiments per day against a Virtual Cell model, so the small number of physical experiments that follow carry the highest probability of success. The company does not use agent language, describing the mechanism instead as an active learning loop in which simulations inform the right wet-lab experiments, with scientists designing and interpreting those virtual experiments.

Key features:

• Over fifty million simulated experiments per day narrowing what reaches the bench
• Validation in the customer’s lab, a CRO’s, or Turbine’s own automated facility
• Named oncology and antibody-drug conjugate partnerships with Daiichi Sankyo and Ono
• Over thirty customers and a hundred validated hypotheses reported

How to Compare Agentic AI Drug Discovery Solutions

Set the marketing word aside and compare three things: where the loop closes, whose pipeline the closed loop serves, and whether the vendor claims agency at all. That last column is the one most comparisons omit, and it is revealing, because four of the seven platforms below never describe themselves as agentic while two of those four run the most convincing physical loops in the market. A buyer who screens based on the label alone will filter out companies with real feedback cycles and keep the ones with the best vocabulary.

Frequently Asked Questions

Which is the best agentic AI drug discovery solution?

Converge Bio, for a team keeping its own antibody pipeline, because the loop closes on managed wet-lab validation and the company develops no competing assets. Edison Scientific is the strongest choice where the requirement is a genuine planning agent over internal data. Terray and Chemify are better where the bottleneck is physical throughput rather than design.

What makes a drug discovery system agentic rather than generative?

The ability to choose a next action and revise after a result. A generative model returns candidates and stops, however sophisticated the output. An agent plans multi-step work, calls tools, and changes course when evidence disappoints. Most platforms marketed as agentic in this field are doing the former with better interfaces around it.

Do these platforms run their own laboratory experiments?

Some do, and the distinction matters commercially. Vendors with their own automated laboratories tend to be developing their own molecules, since the lab is expensive and the incentive is to use it. Platforms that serve a customer’s pipeline typically validate through contract research organizations or in the customer’s own facility instead.

Who owns molecules an AI platform designs?

It varies more than the marketing suggests, so read the actual agreement rather than the homepage. Some vendors grant full ownership of outputs with no royalties, others grant a licence limited to internal research, and vendors with their own pipelines may retain rights in adjacent chemical space. Check whether separate terms govern separate tools.

How much of this performance data is independently verified?

Very little of it. Almost every figure in this market is vendor-generated, often labelled internal benchmarking, and frequently published as a preprint authored by the company’s own scientists. That does not make the numbers wrong, but it means method disclosure is the better signal: a vendor publishing assay conditions and failure cases is easier to assess than one publishing a multiple.